霍奇金与非霍奇金淋巴瘤的非清髓性替代供者移植:LWP-EBMT、Eurocord与CIBMTR比较
该回顾性研究纳入740例18-75岁霍奇金或非霍奇金淋巴瘤患者,比较非清髓性单倍体与无关脐血移植的结局。校正年龄、淋巴瘤亚型和疾病状态后,脐血移植的总生存和无进展生存均低于单倍体骨髓及外周血移植,移植相关死亡率更高。数据支持在HLA不合移植中优先选择单倍体相关供者。
要点
- 脐血移植总生存低于单倍体骨髓移植(HR 1.55)和单倍体外周血移植(HR 1.59)。
- 脐血移植无进展生存低于单倍体骨髓移植(HR 1.44)和单倍体外周血移植(HR 1.86)。
- 脐血移植移植相关死亡率高于单倍体骨髓移植(HR 1.91)和单倍体外周血移植(HR 2.27)。
核心结论
- 对于霍奇金或非霍奇金淋巴瘤的HLA不合移植,数据支持单倍体相关供者移植优于脐血移植。
研究设计与样本
- 回顾性研究纳入740例2009至2016年接受移植的18-75岁霍奇金淋巴瘤(n=283,38%)或非霍奇金淋巴瘤(n=457,62%)患者。
- 数据报告至欧洲血液与骨髓移植学会淋巴瘤工作组、Eurocord或国际血液与骨髓移植研究中心。
- 526例接受单倍体移植,其中68%使用骨髓、32%使用外周血。
- 所有患者接受统一预处理方案(2 Gy全身照射、环磷酰胺和氟达拉滨)及移植物抗宿主病预防(钙调神经磷酸酶抑制剂和霉酚酸)。
- 单倍体移植患者另接受移植后环磷酰胺。
主要发现
- 脐血移植4年总生存和无进展生存分别为49%和36%,单倍体骨髓移植为58%和46%,单倍体外周血移植为59%和52%。
临床怎么用
- 在为霍奇金或非霍奇金淋巴瘤患者考虑HLA不合移植时,可优先选择单倍体相关供者而非脐血供者。
- 单倍体移植可采用统一预处理方案(2 Gy全身照射、环磷酰胺和氟达拉滨)及移植后环磷酰胺进行GVHD预防。
局限性
- 为回顾性研究,可能存在选择偏倚和未校正的混杂因素。
- 仅纳入接受非清髓性预处理的患者,结论不能外推至清髓性移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. PATIENTS AND METHODS: We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide. RESULTS: Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P < .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively). CONCLUSION: When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.
引用
- Fatobene G, Rocha V, St Martin A, et al. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. J Clin Oncol. 2020. PMID: 32031876. doi:10.1200/JCO.19.02408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。